Canada · Delayed Price · Currency is CAD MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of CAD 34.17 million. The enterprise value is 24.18 million.
| Market Cap | 34.17M |
| Enterprise Value | 24.18M |
Important Dates
The last earnings date was Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MediPharm Labs has 427.18 million shares outstanding. The number of shares has increased by 2.31% in one year.
| Current Share Class | 427.18M |
| Shares Outstanding | 427.18M |
| Shares Change (YoY) | +2.31% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 8.70% |
| Owned by Institutions (%) | 0.00% |
| Float | 390.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.82 |
| PB Ratio | 0.96 |
| P/TBV Ratio | 0.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.58 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.69 |
| Quick Ratio | 1.68 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.40 |
| Interest Coverage | -63.58 |
Financial Efficiency
Return on equity (ROE) is -13.22% and return on invested capital (ROIC) is -15.70%.
| Return on Equity (ROE) | -13.22% |
| Return on Assets (ROA) | -5.17% |
| Return on Invested Capital (ROIC) | -15.70% |
| Return on Capital Employed (ROCE) | -11.13% |
| Weighted Average Cost of Capital (WACC) | 9.39% |
| Revenue Per Employee | 326,433 |
| Profits Per Employee | -39,157 |
| Employee Count | 127 |
| Asset Turnover | 0.87 |
| Inventory Turnover | 3.01 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.67% in the last 52 weeks. The beta is 0.93, so MediPharm Labs's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +6.67% |
| 50-Day Moving Average | 0.07 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 57.34 |
| Average Volume (20 Days) | 178,483 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of CAD 41.46 million and -4.97 million in losses. Loss per share was -0.01.
| Revenue | 41.46M |
| Gross Profit | 13.14M |
| Operating Income | -3.94M |
| Pretax Income | -4.97M |
| Net Income | -4.97M |
| EBITDA | -2.41M |
| EBIT | -3.94M |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 10.42 million in cash and 421,000 in debt, with a net cash position of 10.00 million or 0.02 per share.
| Cash & Cash Equivalents | 10.42M |
| Total Debt | 421,000 |
| Net Cash | 10.00M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 35.43M |
| Book Value Per Share | 0.08 |
| Working Capital | 17.88M |
Cash Flow
In the last 12 months, operating cash flow was -981,000 and capital expenditures -63,000, giving a free cash flow of -1.04 million.
| Operating Cash Flow | -981,000 |
| Capital Expenditures | -63,000 |
| Depreciation & Amortization | 1.53M |
| Net Borrowing | -124,000 |
| Free Cash Flow | -1.04M |
| FCF Per Share | -0.00 |
Margins
Gross margin is 31.70%, with operating and profit margins of -9.51% and -12.00%.
| Gross Margin | 31.70% |
| Operating Margin | -9.51% |
| Pretax Margin | -12.00% |
| Profit Margin | -12.00% |
| EBITDA Margin | -5.82% |
| EBIT Margin | -9.51% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.31% |
| Shareholder Yield | -2.31% |
| Earnings Yield | -14.55% |
| FCF Yield | -3.05% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MediPharm Labs has an Altman Z-Score of -2.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.38 |
| Piotroski F-Score | 2 |